Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Research & Development (2016 - 2025)

Spero Therapeutics' Research & Development history spans 10 years, with the latest figure at $5.6 million for Q4 2025.

  • For Q4 2025, Research & Development fell 80.61% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $38.5 million, down 60.24%, while the annual FY2025 figure was $38.5 million, 60.24% down from the prior year.
  • Research & Development reached $5.6 million in Q4 2025 per SPRO's latest filing, down from $8.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $28.8 million in Q4 2024 to a low of $5.6 million in Q4 2025.
  • Average Research & Development over 5 years is $14.9 million, with a median of $14.8 million recorded in 2021.
  • Peak YoY movement for Research & Development: surged 149.47% in 2024, then tumbled 80.61% in 2025.
  • A 5-year view of Research & Development shows it stood at $17.2 million in 2021, then fell by 12.4% to $15.1 million in 2022, then rose by 9.73% to $16.6 million in 2023, then soared by 74.16% to $28.8 million in 2024, then crashed by 80.61% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Research & Development are $5.6 million (Q4 2025), $8.6 million (Q3 2025), and $10.7 million (Q2 2025).